CO:11:2 | Systemic lupus erythematosus with major neuropsychiatric involvement treated with anifrolumab: literature review and a case report
Background. Anifrolumab is a biologic agent approved for the treatment of Systemic Lupus Erythematosus (SLE). Clinical trials evaluating its efficacy (TULIP-1 and TULIP-2) excluded patients with active neuropsychiatric manifestations (NPSLE). The aim of this study was to review the published cases...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
PAGEPress Publications
2025-11-01
|
| Serier: | Reumatismo |
| Fag: | |
| Online adgang: | https://www.reumatismo.org/reuma/article/view/2120 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|